OBJECTIVE: We evaluated survival outcomes of PN and RN for clinical T2 renal masses (cT2RM) controlling for RENAL score.
PATIENTS AND METHODS: Two-center study of 202 patients with cT2RM who underwent RN (122) or PN (80) between 7/2002-6/2012 (median follow-up 41.5 months). Kaplan-Meier analysis compared overall survival (OS), cancer specific survival (CSS) and progression free survival (PFS) among entire cohort and within categories of RENAL score≥10 and <10. association="" between="" procedure="" and="" pfs="" os="" was="" analyzed="" using="" cox-proportional="" hazard="" p=""> RESULTS: No significant differences between PN and RN existed in clinical T stage and RENAL nephrometry. For RN and PN, Five year-PFS was 69.8%/79.9% (p=0.115), CSS 82.5%/86.7% (p=0.407), and OS 80%/83.3% (p=0.291). Cox regression demonstrated no association between RN vs. PN and PFS; RENAL ≥10 was associated with shorter PFS (HR 6.69, p=0.002). Kaplan-Meier analysis for RN vs. PN had no difference in PFS for entire cohort or within RENAL≥10 and <10. pfs="" was="" superior="" for="" renal="" 10="" vs="" p="" 0="" 001="" and="" ct2a="" ct2b="" tumors="" os="" no="" different="" between="" more="" likely="" to="" die="" of="" disease="" or="" any="" cause=""> CONCLUSIONS: PN may be oncologically effective for cT2RM. RENAL≥10 is negatively associated with OS among cT2RM compared to RENAL<10 and="" provides="" additional="" risk="" assessment="" beyond="" clinical="" t="" stage="" further="" follow-up="" prospective="" randomized="" investigation="" is="" requisite="" to="" confirm="" efficacy="" of="" pn="" for="" ct2rm="" p="">
Written by:
Kopp RP, Mehrazin R, Palazzi KL, Liss MA, Jabaji R, Mirheydar HS, Lee HJ, Patel N, Elkhoury F, Patterson AL, Derweesh IH Are you the author?
Department of Urology, UC San Diego Health System, La Jolla, California, USA
Reference: BJU Int. 2013 Nov 26 (Epub ahead of print)
doi: 10.1111/bju.12580
PubMed Abstract
PMID: 24274650
UroToday.com Renal Cancer Section
